Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
format_facet:"Aufsätze"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
topic_facet:"Medical Condition: Smoldering Multiple Myeloma MedDRA version: 21.1Level: PTClassification code 10035226Term: Plasma cell myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Smoldering+Multiple+Myeloma+MedDRA+version%3A+21.1Level%3A+PTClassification+code+10035226Term%3A+Plasma+cell+myelomaSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Smoldering+Multiple+Myeloma+MedDRA+version%3A+21.1Level%3A+PTClassification+code+10035226Term%3A+Plasma+cell+myelomaSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Smoldering+Multiple+Myeloma+MedDRA+version%3A+21.1Level%3A+PTClassification+code+10035226Term%3A+Plasma+cell+myelomaSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (24)
1
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma : A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Medienart: Aufsätze
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Filter aufheben
Thema: Medical Condition: Smoldering Multiple Myeloma MedDRA version: 21.1Level: PTClassification code 10035226Term: Plasma cell myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
Aufsätze
24
E-Artikel
24
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
24
610
Medical Condition: Smoldering Multiple Myeloma ...
24
Phase: Phase 3
Recruitment Status: Authorised-recruitment may ...
24
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
12
2022
8
2021
4
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
24
Englisch
Haven't found what you're looking for?
Wird geladen...